# Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors

> **NCT01878396** · — · UNKNOWN · sponsor: **Istituto Oncologico Veneto IRCCS** · enrollment: 200 (estimated)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Anti-B-RAF

## Key facts

- **NCT ID:** NCT01878396
- **Lead sponsor:** Istituto Oncologico Veneto IRCCS
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-12
- **Primary completion:** 2016-12
- **Final completion:** 2017-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2016-10-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01878396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01878396, "Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01878396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*